Nuvalent Company Profile
What is the competitive landscape for NUVALENT
NUVALENT has one approved drug.
There are four US patents protecting NUVALENT drugs.
Drugs and US Patents for Nuvalent
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuvalent | JIDEYTRO | zidesamtinib | TABLET;ORAL | 220185-002 | Jul 22, 2026 | RX | Yes | Yes | 11,542,278 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Nuvalent | JIDEYTRO | zidesamtinib | TABLET;ORAL | 220185-001 | Jul 22, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Nuvalent | JIDEYTRO | zidesamtinib | TABLET;ORAL | 220185-001 | Jul 22, 2026 | RX | Yes | No | 12,054,498 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nuvalent | JIDEYTRO | zidesamtinib | TABLET;ORAL | 220185-002 | Jul 22, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Nuvalent | JIDEYTRO | zidesamtinib | TABLET;ORAL | 220185-001 | Jul 22, 2026 | RX | Yes | No | 12,043,626 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Nuvalent | JIDEYTRO | zidesamtinib | TABLET;ORAL | 220185-001 | Jul 22, 2026 | RX | Yes | No | 11,542,278 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nuvalent Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2023525038 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2023056405 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2021226208 | ⤷ Start Trial |
| China | 115916754 | ⤷ Start Trial |
| China | 118234725 | ⤷ Start Trial |
| Australia | 2021268664 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |

